A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects

NCT01114607 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: GSK1605786 ChemoCentryx: formulation A
DRUG: GSK1605786 GSK: formulation B
DRUG: GSK1605786 GSK direct-fill: formulation C
DRUG: GSK1605786 GSK modified-process: formulation D
DRUG: GSK1605786 GSK tablet: formulation E

Sponsor

GlaxoSmithKline